-- Mr. O’Day Brings Global Pharmaceutical Leadership ExperienceAcross Geographies and Therapeutic Areas --
-- Appointment Effective March 1, 2019 --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 10, 2018--
Gilead Sciences, Inc. (Nasdaq: GILD) announced todaythat its
Board of Directors has named Daniel O’Day Chairman of the Board and
Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently
the CEO of Roche Pharmaceuticals. He has held the position since 2012,
and prior to that led Roche Diagnostics. His career spans three decades
of diverse leadership roles across North America, Asia Pacific and
Europe.
The Board has also appointed Gregg Alton as interim Chief Executive
Officer for the period of January 1, 2019 until Mr. O’Day’s start date
of March 1, 2019. Mr. Alton has held a number of executive positions at
Gilead over the past 20 years, with experience in legal, medical
affairs, policy and commercial. He previously served as general counsel
and in August of this year, was appointed Chief Patient Officer.
“Following a comprehensive search, the Board became convinced that Dan
is the right leader to bring Gilead into the future,” said John C.
Martin, PhD, Chairman, Gilead Sciences Board of Directors. “He is
uniquely qualified to take on this role given his track record of
success in highly scientific and competitive therapeutic areas, deep
understanding of the evolving healthcare environment around the world,
and unwavering commitment to driving innovation across all aspects of a
business, which will serve Gilead and our stakeholders well.
Additionally, Dan brings expertise and values that are aligned with our
organization, and I, along with Gilead’s entire Board, am confident in
his ability to work alongside our talented leadership team and deliver
on our ambitious goals.”
After joining Roche Pharmaceuticals in 1987, Mr. O’Day held various
positions in the United States before moving to Roche headquarters in
Switzerland in 1998. During his time in Switzerland, he held leadership
roles in Global Marketing and Lifecycle Management. In 2001, he moved to
Tokyo to become Head of Corporate Planning for Roche Pharmaceuticals in
Japan and later moved to Denmark to serve as General Manager. He became
President of Roche Molecular Diagnostics in California in 2006 and
subsequently returned to Roche headquarters to lead the Diagnostics
Division before assuming his current position. He is a member of the
corporate executive committee of F. Hoffmann La Roche AG and a member of
the boards of Shanghai Roche Pharmaceuticals Ltd., Roche (China)
Holding, Roche Pharma Schweiz AG, Genentech, Inc., Chugai
Pharmaceuticals Co., Ltd., Flatiron Health, Inc., and Foundation
Medicine, Inc. Additionally, he has served as a member of the board of
the European Federation of Pharmaceutical Industries and Associations.
Mr. O’Day holds a Bachelor of Science in Biology from Georgetown
University in Washington, D.C. and an MBA from the Columbia Business
School at Columbia University in New York.
“I have long admired Gilead for its work to develop medicines that have
fundamentally changed the way HIV and viral hepatitis are treated. The
company has successfully grown into a global organization, providing
access to people around the world, while maintaining its focus on
innovative science,” said Mr. O’Day. “Together with the Board,
leadership team and Gilead’s 11,000 employees, I look forward to
building on this in ways that I believe will – in keeping with Gilead’s
mission – transform the lives of millions of individuals.”
As previously announced, Dr. Martin will step down from the company’s
Board of Directors, effective March 1, 2019, Mr. O’Day’s first day of
employment. Also as previously announced, John F. Milligan, PhD, will
step down from his role as President and Chief Executive Officer and as
a member of the Board at the end of 2018.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters
in Foster City, California.
Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2018, as filed
with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
statements.
For more information about Gilead at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181209005030/en/
Source: Gilead Sciences, Inc.
Sung Lee, Investors(650) 524-7792
Amy Flood, Media(650) 522-5643
